rs8177374 — TIRAP Ser180Leu

TIRAP Ser180Leu — The Immunity Sweet Spot

Your immune system's first line of defense against bacteria depends on sensing microbial invaders through a family of receptors called Toll-like receptors (TLRs). TIRAP (also known as MAL)¹¹ TIRAP (also known as MAL)
TIR domain-containing adaptor protein; bridges activated TLR2 and TLR4 receptors to the downstream signalling protein MyD88 is an essential adaptor molecule in this alarm system. The Ser180Leu variant (rs8177374) subtly alters the shape of TIRAP's TIR domain, changing how strongly it bridges the receptor to the signaling cascade. The result is one of genetics' clearest illustrations of balancing selection²² balancing selection
evolutionary pressure that maintains two alleles because each is advantageous in different conditions or gene doses — carrying one copy of the leucine variant appears to tune innate immunity into an optimal protective state, while carrying two copies tips the balance in the opposite direction.

The Mechanism

When bacteria invade, Gram-negative bacterial lipopolysaccharide (LPS) activates TLR4, while Gram-positive bacterial lipoproteins activate TLR2³³ Gram-negative bacterial lipopolysaccharide (LPS) activates TLR4, while Gram-positive bacterial lipoproteins activate TLR2
These are the two major innate immune receptors for bacterial threats. Both receptors recruit TIRAP to bridge them to MyD88, which then activates NF-κB and triggers production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-8.

Serine 180 sits in a surface-exposed cavity of the TIRAP TIR domain. The S180L substitution replaces a small polar amino acid with a bulky hydrophobic leucine⁴⁴ The S180L substitution replaces a small polar amino acid with a bulky hydrophobic leucine
This causes steric occlusion of the binding cavity, likely altering the geometry of receptor-adaptor interactions. The result is reduced efficiency of MyD88 recruitment and a modestly attenuated downstream signaling response. Crucially, this attenuation appears to affect signaling intensity rather than completely abolishing it — heterozygous carriers still mount effective immune responses, but with less inflammatory overshoot.

In homozygous carriers (TT), an unexpected paradox emerges: rather than simply further dampening the response, structural modelling suggests the altered protein-protein geometry leads to an abnormal signaling configuration, and clinical studies found that TIRAP 180L homozygous patients with Gram-negative bacterial sepsis showed a paradoxical cytokine overshoot⁵⁵ clinical studies found that TIRAP 180L homozygous patients with Gram-negative bacterial sepsis showed a paradoxical cytokine overshoot
Significantly more severe infection and decreased tissue oxygenation compared with CC and CT genotypes.

The Evidence

The landmark study came from Khor et al. in Nature Genetics 2007⁶⁶ Khor et al. in Nature Genetics 2007
Case-control study of 6,106 individuals from Gambia, Kenya, United Kingdom, and Vietnam, screening 33 TLR pathway SNPs against four serious bacterial infectious diseases. TIRAP Ser180Leu heterozygosity was the standout finding, independently protecting against all four conditions studied: invasive pneumococcal disease (OR 0.59, P=0.003), bacteremia (OR 0.40, P=0.003), malaria (OR 0.47, P=0.002), and tuberculosis (OR 0.23, P=0.008). The combined p-value across all diseases was 9.6 × 10⁻⁸ — well beyond genome-wide significance — and the protective effect was seen in both African and European populations.

A 2009 PNAS study⁷⁷ A 2009 PNAS study
Functional and genetic analysis in German patients with Gram-negative bacterial sepsis extended these findings and provided the evolutionary context: the T allele appears to have been positively selected because heterozygosity confers an advantage against the most common bacterial killers, but homozygosity creates a vulnerability. This balanced polymorphism pattern — where the heterozygous state is optimal — explains why the variant persists at 10–13% frequency in European populations rather than sweeping to fixation.

Multiple independent studies have confirmed the protective role of S180L heterozygosity in tuberculosis specifically. Multiple replication cohorts across populations confirmed the protective association, and research from Colombia confirming protection against TB and SLE⁸⁸ research from Colombia confirming protection against TB and SLE
Castiblanco et al. 2008, OR 0.53 for TB, OR 0.29 for SLE in 1,325 Colombian subjects broadly replicated the protection against tuberculosis.

The variant also shows intriguing autoimmune associations. A study of systemic lupus erythematosus (SLE) found the Leu180 allele reduced SLE risk by approximately 73%⁹⁹ A study of systemic lupus erythematosus (SLE) found the Leu180 allele reduced SLE risk by approximately 73%
Consistent with the idea that stronger innate immune activation contributes to autoimmune pathology. Conversely, TIRAP Ser180Leu was positively associated with Behcet's disease in UK patients¹⁰¹⁰ TIRAP Ser180Leu was positively associated with Behcet's disease in UK patients
A mucosal inflammatory disorder where increased cytokine production at lesion sites worsens disease persistence, illustrating that the T allele's effects depend on disease context.

Practical Implications

For heterozygous CT carriers, the data paint an encouraging picture: your innate immune system appears to be calibrated toward effective defense against common bacterial pathogens without excessive inflammatory collateral damage. This is not a license to ignore infection prevention, but it is a genuine genetic advantage for resisting a broad class of serious infections.

For homozygous TT carriers (approximately 3% of Europeans), the situation is more nuanced. The same variant that protects heterozygotes becomes a potential liability at the homozygous state — particularly in the context of severe Gram-negative bacterial infections or surgical sepsis. Standard vigilance around infection prevention and prompt treatment of bacterial infections is important.

The TIRAP pathway also interacts functionally with the TLR4 receptor variants already in this database (rs4986790 Asp299Gly and rs4986791 Thr399Ile). Both receptor and adaptor variants affect the same LPS-sensing cascade, and individuals carrying variants in both genes may show compounded modulation of innate immune responses.

Interactions

TIRAP Ser180Leu sits functionally downstream of rs4986790 (TLR4 Asp299Gly)¹¹¹¹ rs4986790 (TLR4 Asp299Gly) and rs4986791 (TLR4 Thr399Ile)¹²¹² rs4986791 (TLR4 Thr399Ile). Since TIRAP bridges TLR4 to MyD88, carrying functional variants in both TLR4 and TIRAP affects the same signaling cascade at two points. The TLR4 variants reduce receptor sensitivity to LPS; TIRAP Ser180Leu modulates how efficiently the activated receptor signal is propagated downstream. Combined variant carriers may show additive dampening of TLR4-mediated innate immune responses.

The MyD88 rs6853 variant is a related pathway partner — MyD88 is the downstream target that TIRAP recruits. Studies of pulmonary tuberculosis have examined both TIRAP rs8177374 and MyD88 rs6853 simultaneously, finding independent protective effects for both, suggesting these adaptor variants can combine to shape tuberculosis susceptibility through the same MyD88-dependent pathway.